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c-myc pathwayMembers of the Orai family are highly selective calcium ion channels that play an important role in
store-operated calcium entry. Among the three known Orai isoforms, Orai3 has gained increased attention,
notably for its emerging role in cancer. We recently demonstrated that Orai3 channels are over-expressed
in breast cancer (BC) biopsies, and involved speciﬁcally in proliferation, cell cycle progression and survival
of MCF-7 BC cells. Here, we investigate the downstream signaling mechanisms affected by Orai3 silencing,
leading to the subsequent functional impact speciﬁcally seen in MCF-7 cancer cells. We report a correlation
between Orai3 and c-myc expression in tumor tissues and in the MCF-7 cancer cell line by demonstrating
that Orai3 down-regulation reduces both expression and activity of the proto-oncogene c-myc. This is likely
mediated through the MAP Kinase pathway, as we observed decreased pERK1/2 levels and cell-cycle arrest
in G1 phase after Orai3 silencing. Our results provide strong evidence that the c-myc proto-oncogene is
inﬂuenced by the store-operated calcium entry channel Orai3 through the MAP kinase pathway. This connec-
tion provides new clues in the downstream mechanism linking Orai3 channels and proliferation, cell cycle
progression and survival of MCF-7 BC cells.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The recent discovery of the Orai channels as the pore forming units
of the Ca2+ selective CRAC channels opened a new era in the ﬁeld of
store-operated calcium entry (SOCE) [1]. Three distinct Orai isoforms
have been described to date (Orai1, Orai2 and Orai3), with Orai3
being “special” in this family, notably because of its exclusive presence
in mammals [2] and its receptivity to pharmacological modulation [3].
CRAC channels are known for their physio-pathological roles [1,4–6],
but their involvement in BC is only emerging [7–9]. For instance, we
have recently reported that Orai3 channels are over-expressed in BC
biopsies, and have also shown that these channels are involved in
proliferation, cell cycle progression and survival of BC cells by regulating
theG1 phase andG1/S transition regulator proteins [9].Moreover, these
effects are speciﬁc to cancer cells, since down-regulation of Orai3 chan-
nels does not affect either cell proliferation or cell survival of normald calcium entry; TMAs, Tissue
33 322827644.
33 322827644.
. Ahidouch),
l rights reserved.breast cells [9]. How Orai3 impacts such essential processes of the
cancer cells' life remains elusive, and we therefore aimed at deciphering,
at least in part, the mechanisms linking Orai3 and the above described
cellular effects.
The ubiquitous SOCE pathway is not only necessary to reﬁll internal
calcium stores, but also for activating downstream signaling cascades
[10,11]. Thus, on the assumption that at least one transcription factor
was involved, we directed our interest to the c-myc pathway that
has been implicated, just like Orai3, in processes controlling cell cycle
progression, proliferation and apoptosis [12,13]. The proto-oncogene
c-myc encodes a transcription factor of the helix–loop–helix/leucine
zipper protein family, and is known to be regulated by calcium [14]
and several calcium-dependent signaling pathways such as the MAP
kinase and the calcineurin/NFAT pathways [15–17].
Most human cancers display enhanced c-myc expression and/or
deregulated c-myc activity [18–20]. In BC, several studies have shown
that between 50% and 100% of BC cases display increased c-myc protein
levels (see [21] for review). Over-expression of c-myc is associatedwith
reduced relapse-free and overall survival in BC patients [22,23]. Inter-
estingly, down-regulation of c-myc in BC cells induces cell cycle arrest
and apoptosis [24,25]. C-myc has been shown to be the key factor in
G1 progression and G1/S transition phases in many cell types [26,27].
In fact, c-myc positively regulates the expression and/or activity of
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additionally suppresses cyclin-dependent kinase inhibitors (CDKIs)
such as p15, p21 and p27 [13]. These effects are strikingly similar to
the effects seen with Orai3 down-regulation, which also alters cyclins
D1 and E, CDKs 4 and 2, the cyclin-dependent kinase inhibitor
p21Waf1/Cip1, and the tumor-suppressing protein p53 [9].
Therefore,wehypothesized thatOrai3 channelsmight be anupstream
regulator of the c-myc pathway, and we investigated the role of c-myc
in the Orai3-induced differential effect on proliferation and cell cycle
progression in BC cells and normal breast cells. Using qRT-PCR and tissue
microarray, we found that expression levels of Orai3 and c-myc are
positively correlated. We observed that Orai3 down-regulation induced
cell cycle arrest in G1 phase through the c-myc pathway. We also found
that simultaneous down-regulation of both Orai3 and c-myc proteins
hadno additive or synergic effects on either BC cell proliferation or surviv-
al. Finally, since the MAP Kinase pathway is known to regulate c-myc
protein expression and activity, we investigated the effect of Orai3
down-regulation on ERK1/2 phosphorylation and found that the phos-
phorylation level of ERK1/2 signiﬁcantly decreased after silencing Orai3
channels.
Our results therefore suggest that Orai3 channels are amongst
upstream effectors of the oncogenic c-myc pathway and constitute
key players in BC cells such as the MCF-7 cell line. Importantly, based
on the differential effect seen between normal and BC cells, Orai3
could represent a selective target for breast cancer treatment.
2. Materials and methods
2.1. Tissue microarrays
Cancerous breast tissue was obtained from fresh surgical specimens.
Consent forms (approved by the University Hospital of Amiens) were
signed by the patients before surgery to allow the use of a portion of tis-
sue samples for research purposes. Samples of breast adenocarcinoma,
as well as non-tumoral tissues from the same patient were obtained
from women having undergone operations at the Amiens hospitals.
Immunohistochemical staining was performed on formalin-ﬁxed
parafﬁn-embedded (FFPE) blocks with a Roche Ultra immunostainer,
using antibodies against Orai3 (1:100, HPA015022, Sigma Prestige
Antibody) and c-myc (1:100, N-262, Santa-Cruz BioTechnologies).
This was followed by the avidin–biotin–peroxidase complex tech-
nique. Reactions were developed using a chromogenic reaction in
DAB (diamino-3,3'benzidinetetrahydrochloride) substrate solution
(DAB, Sigma Fast). Counterstaining was carried out with hematoxylin
solution. Micrograph acquisitions were performed using a digital
camera connected to a Zeiss microscope.
Immunostaining in the tumor tissue was determined by subjective
visual scoring of the brown stain. Two operators independently
evaluated antigen expression. Scoring of the intensity of the staining
was performed according to an arbitrary scale with steps of 0, 1, 2,
and 3 where “0” was considered to be absence of staining, “1” consid-
ered weak staining, “2”was considered asmoderately positive staining,
and “3” was considered to be strong staining. A negative control was
performed using the same technique without primary antibody.
The expression of Orai3 and c-myc was also assessed in 30
additional human invasive ductal adenocarcinoma specimens using
Tissue Microarray (TMAs). Brieﬂy, four-micrometer-thick sections of
formalin-ﬁxed parafﬁn-embedded tissue samples were taken from
the FFPE block.
2.2. Immunoﬂuorescence
Immunoﬂuorescent analyses were performed on tissues following
a published protocol [29]. Antibodies used were anti-Orai3 (1:100,
HPA015022, Sigma Prestige Antibody), anti-c-myc (9E10, 1:500, Santa
Cruz Biotechnology, Inc., Heidelberg, Germany), goat anti rabbit IgGDyLight 549 conjugated (Thermo, Rockford, IL, USA), and Alexa Fluor
488 goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA). Nuclei
were stained with DAPI (4′,6-diamidino-2-phenylindole, 1.43 μM). Im-
ages were obtained using a Zeiss Axiovert 200 microscope equipped
with ApoTome system (Zeiss, Le Pecq, France).
2.3. Cell culture
MCF-7 BC cells were grown in Eagle's Minimum Essential Medium
supplemented with 5% fetal calf serum (Lonza, Levallois-Perret,
France), 2 mM L-glutamine, and 0.06% HEPES. The immortalized
human mammary epithelial cell line MCF-10A was grown in DMEM/
F12 medium, composed of Dulbecco's modiﬁed Eagle's medium/
nutrient mixture F12 supplemented with 5% fetal calf serum, 20 ng/ml
epidermal growth factor, 10 mg/ml-1 insulin, 0.5 mg/ml hydrocortisone,
and 100 ng/ml cholera toxin (Sigma-Aldrich, St-Quentin Fallavier,
France). All cell lines were grown in a 5% CO2-humidiﬁed incubator
at 37 °C.
2.4. Transfection
Transfection of cells was performed using the nucleofection tech-
nology (Amaxa, Köln, Germany), as previously described [30]. Cells
(1×106) were transfected either with 5 μg scrambled siRNA as a con-
trol (siGENOME non-targeting siRNA, Dharmacon Research Inc.,
Chicago, IL, referred in the text to as “si-CTL”), or with siRNAs directed
against an Orai isoform (Orai1 or Orai3), or with siRNA directed
against c-myc, or simultaneously with both si-Orai and si-c-myc. To
this end, siRNA were combined and nucleofected according to the
manufacturer's protocol.
2.5. Real-time quantitative PCR
Extraction of total RNA from cell lines or biopsies and real-time
PCR were performed as previously described [9]. The relative amount
of Orai3 and c-myc mRNAs in breast cancer cells were normalized to
the endogenous control (ß-actin) and compared to the reference
sample (normal breast cells) using the Pfafﬂ method [31]:
Ratio ¼
Etarget
 Δct
target normalcells−cancercellsð Þ
Erefð ÞΔctref normalcells−cancercellsð Þ
2.6. Western blot analyses
Whole-cell lysates were preparedwith RIPA buffer containing a pro-
tease inhibitor cocktail (Sigma-Aldrich). Proteinswere separated by de-
naturing SDS–PAGE, and transferred onto nitrocellulose membranes.
The primary antibodies used were: anti-Orai3 (1:100, HPA015022,
Sigma Prestige Antibody), anti-c-myc (N-262, 1:500, Santa Cruz Bio-
technology Inc., Heidelberg, Germany), anti-ERK1/2 and anti-pERK1/2
(1:1000, Cell Signaling Tech., Danvers, MA). Secondary antibodies
were coupled to horseradish peroxidase. Actin antibody (1/2000,
Santa Cruz Biotechnology) was used for loading control experiments.
Bound antibodies were visualized using ECL chemiluminescent
substrate (GE Healthcare, Saclay, France) and quantiﬁed using the
Bio-Rad image acquisition software (Quantity One) associated with
the ChemiDoc XRS imager system (Bio-Rad Laboratories).
2.7. c-myc activity measurement
Nuclear extracts were obtained using the Marligen Biosciences Kit.
Brieﬂy 72 h after transfection, cells were collected by centrifugation
and washed in PBS. Cells were then allowed to swell in Complete
Hypotonic Cell Lysis Buffer, and lysis was facilitated by the addition
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centrifugation, and the cytoplasm was removed. The nuclear pellet
was washed twice in Complete Nuclear Wash Buffer and extractedby addition of Complete Extraction Buffers. The nuclear extract was
clariﬁed by centrifugation, and the protein concentration was deter-
mined using a Bradford assay. Direct quantitation of c-myc binding
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ity measurement Kit (Marligen Biosciences).
2.8. Cell viability and mortality
Cell viability and mortality were measured 72 h post-transfection
using TrypanBlue assay. After transfectionwith siRNAs directed against
Orai3 or c-myc or with non-targeting siRNA, MCF-7 cells were grown
in 35 mm Petri dishes at a density of 1×105 cells for 72 h. Cell count
was assessed using the standard Malassez cell method. Brieﬂy, cells
were removed by trypsinization and diluted in Trypan Blue solution.
Cell counts were performed six times and the results were expressed
as the percentage of viable or dead cells normalized to control.
2.9. Cell-cycle analysis
For the measurement of cellular DNA content, only adherent
cells were collected at 72 h post-transfection. Cells were pelleted,
re-suspended in PBS/EDTA, treated with 20 mg/ml RNaseA (Sigma-
Aldrich) and stained with 50 mg/ml of propidium iodide (Sigma-
Aldrich). Samples were then analyzed on an Elite Beckman Coulter
ﬂow cytometer. The percentage of cells in different phases was cal-
culated using WinMDI 2.8 and Cylchred software.
2.10. Determination of p42/p44 MAP Kinase/extracellular signal regulated
kinase (ERK1/2) by western blotting
The level of phosphorylation of ERK1/2 treated with either si-CTL
or si-Orai3 was examined in MCF-7 cells. Forty-eight hours after
transfection, MCF-7 cells were deprived of FCS for 24 h. The medium
was then changed to a fresh medium, either without FCS or with 5%
FCS. Cells were incubated for 20 minutes in this medium before pro-
tein extraction.
2.11. Statistical analyses
Values are expressed as mean±SEM. Statistical analysis of the
data was performed using appropriate ANOVA, Mann–Whitney or
paired t-tests. Differences were considered signiﬁcant at pb0.05.
3. Results
3.1. Correlation between Orai3 and c-myc expression in tumor tissues
and in BC cell lines
In our previous study, we showed that Orai3 is over-expressed in
77% of the studied tumor samples [9]. Because of this, and the fact
that c-myc expression is frequently ampliﬁed in breast cancer, we
assessed the expression levels of c-myc mRNA in the same BC sam-
ples previously used for the evaluation of Orai3 expression. We
found that c-myc was over-expressed (over-expression being deﬁned
as a two-fold or greater mRNA level when compared to the expres-
sion levels found in normal adjacent breast tissue) in 9 cases out of
13 (69.2%, Supplementary Fig. 1). Statistical analysis based on the
Spearman's correlation coefﬁcient (Fig. 1A) indicated a positive corre-
lation between Orai3 and c-myc mRNA expression (R=0.857). The
expression of Orai3 and c-myc was also evaluated in 30 additional
human invasive adenocarcinoma specimens using TMAs (Fig. 1B).Fig. 1. Correlation between Orai3 and c-myc genes expression in breast cancer. A: Spearman
coefﬁcient is equal to 0.857. B: Mean score of Orai3 and c-myc staining obtained on the ad
Orai3 and c-myc expression in cancerous and matched non-tumoral human breast cancer ti
were subjected to immunoperoxidase staining, as described in Materials and methods. Orig
Merging of both Orai3 and c-myc staining is shown in δ, and DAPI colored nuclei are show
breast cell line MCF-10A taken as reference for both genes (n=4). mRNAs are normalizedHere too, considering over-expression is at least a two-fold higher
expression, Orai3 and c-myc were over-expressed in 70% (21 out of
30 cases) and 80% (24 out of 30 cases) cases respectively (pb0.001
by Mann–Whitney Rank Sum Test). Moreover, of the 21 samples
exhibiting high expression of Orai3 (score≥2+), a high c-myc
staining (score≥2+) was found in all samples (100%). Statistical
analysis based on the Spearman's correlation coefﬁcient indicated
again a positive correlation between Orai3 and c-myc protein expres-
sion (R=0.895). A representative immuno-histochemistry is shown
in Fig. 1C. Double immuno-ﬂuorescence was also performed to assess
co-overexpression of Orai3 and c-myc in FFPE tissues from the BC
patients. A representative immuno-ﬂuorescence is shown in Fig. 1D.
Although some cells express either predominantly c-myc or Orai3, a
majority of cells show concomitant over-expression of both proteins.
Together, these results indicate that Orai3 and c-myc are strongly
correlated in BC tissues.
To test the involvement of c-myc in Orai3-dependent cell prolifera-
tion and/or survival, we ﬁrst studied c-myc mRNA expression levels
in both normal and cancer breast cells. As shown in Fig. 1E, expression
of c-myc, as assessed by RT-qPCR, is higher in the MCF-7 cancer cell
line than in the non-cancerous MCF-10A cell line. Remarkably, this
over-expression (2.2±0.5 fold over control) is very similar to the Orai3
over-expression seen in these cancer cells (2.4±0.2 fold over control).
3.2. Orai3 down-regulation reduces c-myc expression and activity
Wenext silenced Orai3 channelswith small interfering RNAs in both
cell lines. As can be seen in Fig. 2A, siRNAs against c-myc were effective
in both normal and cancer cell lines. Moreover, si-Orai3 was able to
down-regulate c-myc mRNA expression only in MCF-7 cancerous
cells. Therefore, we assessed the extent of down-regulation at the pro-
tein level, again at 72 h post-transfection, using Western blotting. The
c-myc expression is shown in Fig. 2B and densitometric analyses of
c-myc bands are presented in Fig. 2C. The results at the protein level
are consistent with those obtained at the mRNA level, c-myc protein
levels being strongly reduced only in MCF-7 cells tranfected with
si-Orai3 (43.1±8.7% of the control value, pb0.05). Interestingly, we ob-
served no signiﬁcant difference in c-myc expression levels between
si-Orai3 treated MCF-10A cells and MCF-10A control cells.
We next sought to evaluate the c-myc/Max activity in normal and
cancer cells. Indeed, it is known that c-myc belongs to the Myc/Max/
Mad network that is composed of a group of transcription factors,
whose interactions result in transcriptional activation or repression
of their target genes [12,32]. Max is the protein partner of c-myc,
whose heterodimerization allows binding to speciﬁc DNA sequences
located in c-myc target genes and permits the recruitment of tran-
scriptional co-activators. This process results in the activation of the
c-myc downstream genes, particularly those involved in cell cycle
progression and proliferation. In this context, we measured the
Myc/Max complex DNA-binding, which reﬂects c-myc activity. In BC
cells, Orai3 silencing resulted in a highly signiﬁcant decrease of
c-myc activity (3.6±0.5% vs. 100±30.3% in the control, pb0.001,
Fig. 2D). In contrast, the effect observed in MCF-10A cells was not
statistically signiﬁcant (54±21% vs. 100±37.7% in control, Fig. 2D).
To know whether reduction in c-myc expression and activity
are really speciﬁc to Orai3 down-regulation or could also be observed
with silencing of another member of the Orai protein family, we choose
to down-regulate Orai1, also present in MCF-7 cells [8]. The results are's correlation between Orai3 mRNA and c-myc mRNA extracted from 13 patients: the R
ditional cohort of 30 patients represented on the TMA. C: Representative examples of
ssues, as assessed by immunohistochemistry. Parafﬁn sections of human breast tissues
inal magniﬁcation: ×400. D: Immunoﬂuorescent staining of c-myc (β) and Orai3 (γ).
n in α. E: Relative transcript levels of Orai3 and c-myc in MCF-7 cells, with the normal
to ß-actin, as described in Materials and methods.
Fig. 2. Orai3 down-regulation affects c-myc protein expression and activity. A: Relative transcript levels of c-myc in MCF-10A and MCF-7 cells after transfection with either si-c-myc
or si-Orai3, with a non-targeting si-RNA (si-CTL) taken as reference for both genes (n=3). B: Representative western blot showing the effects of cell transfection with si-control
(si-CTL) or si-Orai3 on the expression of c-myc in both MCF-7 and MCF-10A cell lines. C: Quantiﬁcation of c-myc levels using densitometric analyses of c-myc protein expression
shown in B (n=4). D: c-myc activity measured in cells transfected with si-Orai3, normalized to c-myc activity measured under control condition in MCF-7 cells (n=9) and in
MCF-10A cells (n=6). Values are reported as mean±SD, *pb0.05; ***pb0.001 vs. control; ns: not signiﬁcant.
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c-myc promoter activity was found when Orai1 was down-regulated
(226±11.17% vs. si-CTL, data not shown). Consistently, si-Orai1 in-
duced an upregulation of c-myc mRNA (180±35.7%, Supplementary
Fig. 2A). Quantitation of c-myc binding activity was also performed
using the Myc–Max activity measurement kit: again, the activity of
si-Orai1 treated cells was increased to 183.4±5.3% when compared to
the si-CTL condition (Supplementary Fig. 2B).
Taken together, these results showed that Orai3 down-regulation
reduced both c-myc protein expression and activity levels exclusively
in BC cells, since no statistically signiﬁcant effect was detected in
normal cells. While, silencing Orai1 led to the opposite effect in BC
cells (increase of c-myc mRNA expression and activity).
3.3. c-myc-dependent proliferation and survival are regulated by Orai3
in BC cells
Given the results obtained for c-myc expression and activity,
we next investigated the contribution of c-myc to Orai3-dependentproliferation and survival. Cells were transfected with different siRNAs
independently (siCTL and siRNAs directed against Orai3 or c-myc) or
combined (si-Orai3+si-c-myc). At 72 h post-transfection, a Trypan
Blue assay was performed to assess the number of viable cells and the
percentage of cell mortality for each condition. As expected, Orai3 and
c-myc silencing signiﬁcantly decreased BC cell viability to 34.6±4.1%
and 34.7±2.9% of the control, respectively (pb0.001, Fig. 3A) and
increased cell mortality (16.5±1.3% in si-Orai3 transfected cells,
16.1±0.6% in si-c-myc transfected cells vs. 6.3±0.5% in control cells,
pb0.001, Fig. 3B). Interestingly, the effects of si-Orai3 and si-c-myc on
cell viability and mortality were not additive when cells were simulta-
neously treated with both siRNAs (Fig. 3A and B).We also checked the
percentage of apoptotic cells after siRNA treatments. As shown in
Supplementary Fig. 3, apoptosis increased signiﬁcantly in si-Orai3,
si-c-myc and both si-Orai3 and si-c-myc conditions. Interestingly,
values for apoptosis in si-Orai3, as well as in si-c-myc treated cells
(either alone or combinedwith si-Orai3)were not statistically different.
InMCF-10A cells, Orai3 down-regulation had no effect on either cell
viability or cell mortality. In these cells, c-myc silencing signiﬁcantly
Fig. 3. c-myc involvement in Orai3-dependent proliferation and survival. A: Effects of Orai3 and c-myc silencing on MCF-7 cell viability. The cell viability was measured 72 h post
transfection, and all values were normalized as percentage of si-CTL. B: Percentages of cell mortality obtained in MCF-7 cells transfected with si-Orai3 and/or si-c-myc for 72 h.
C: Effects of Orai3 and c-myc silencing on MCF-10A cell viability at 72 h post-transfection. Values were normalized as percentage of siCTL. D: Effects observed on MCF-10A mortality
after transfection with si-Orai3 and/or si-c-myc for 72 h. Values are reported as mean±SEM of triplicate experiments, ***pb0.001 vs. control; ns: not signiﬁcant.
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but had no effect on cell mortality (Fig. 3D). The effects of combined
si-Orai3 and si-c-myc treatments were not statistically different from
those given by si-c-myc alone on MCF-10A with respect to viability or
mortality (Fig. 3C and D). These results are further evidence of the in-
volvement of c-myc in the Orai3-dependent cell proliferation and sur-
vival of breast cancer cells.
3.4. Orai3 down-regulation induced cell arrest in G1 phase through the
c-myc pathway
We have previously shown that Orai3 silencing induced cell
cycle arrest in the G1 phase [9]. To determine the contribution of
c-myc to this effect, we investigated the cell cycle distribution of
cells transfected with siRNAs against Orai3 and/or c-myc. At 72 h
post-transfection, cell cycle analysis was performed by ﬂow cytome-
try. Fig. 4A shows the cell cycle distribution of MCF-7 BC cells. Consis-
tent with previous observations [9], Orai3 silencing led to cell cycle
arrest, with a signiﬁcant accumulation of cells in the G0/G1 phase
(76.8±3.1% vs. 55.6±1% for the control condition, pb0.01). Therewas a decrease in the cell percentage in both S (16±2.8% vs. 31±
0.8% for the control condition) and G2/M (7.3±0.3% vs. 13.5±0.3%
for the control condition) phases. When c-myc was down-regulated,
we observed a signiﬁcant increase of cells in the G0/G1 phase (69±
0.7% vs. 55.6±1% for the control condition, pb0.001), a signiﬁcant
decrease in the cell percentage in S phase (18.4±0.7% vs. 31±0.8%
for the control condition) and no signiﬁcant effect on G2/M
phase (12.6±0.1% vs.13.5±0.3% for the control condition). Cells
co-transfected with both siRNAs showed no signiﬁcant additive ef-
fect, and the cell distribution under this condition was similar to
that observed in cells transfected with si-Orai3 alone. As expected,
cell cycle distribution of MCF-10A cells was unchanged in cells with
down-regulated Orai3 when compared to the control condition
(Fig. 4B). In contrast, c-myc silencing resulted in cell cycle arrest,
with a signiﬁcant accumulation of cells in the G0/G1 phase (69.5±
4.6% vs. 59.5±2.9% for the control condition, pb0.05), and a decrease
in the cell percentage in G2/M phase (17.4±3.9% vs. 24.1±3.3% for
the control condition, pb0.05), while no signiﬁcant effect was
detected in S phase. When combined, si-Orai3 and si-c-myc induced
the same effects as si-c-myc alone.
Fig. 4. c-myc involvement in Orai3-dependent cell cycle progression. A: Cell cycle distribution of MCF-7 cells transfected with siRNAs against Orai3 (si-Orai3) and/or c-myc
(si-c-myc). B: Cell cycle analysis of MCF-10A cells in the same experimental conditions. The cell cycle analysis was performed at 72 h post-transfection. Insets show raw data
from the FACS acquisition software. Values are reported as mean±SEM of triplicate experiments, *pb0.05;**pb0.01; ***pb0.001 vs. control; ns: not signiﬁcant.
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Kinase pathway
We evaluated c-myc protein expression levels after either individ-
ual or concomitant down-regulation of Orai3 and c-myc (Fig. 5A).
While separate transfections of either si-Orai3 or si-c-myc induced a
decrease of c-myc protein expression to a similar extent (approxi-
mately 40% decrease, pb0.01), the combined transfection of both
siRNAs had no additive effects (ca. 50% down-regulation, without sta-
tistical signiﬁcance with respect to individual siRNAs).
We sought to determine which pathway was most likely involved
in the c-myc down-regulation induced by Orai3 silencing. The MAP
Kinase pathway is known to control the c-myc promoter. We there-
fore investigated the level of phosphorylation of ERK1/2 in MCF-7
cells treated with either si-control (si-CTL) or si-Orai3. Stimulation
with 5% serum induced approximately a 8.8 fold increase of the
ERK1/2 phosphorylation in cells treated with si-CTL (Fig. 5B). In
si-Orai3 treated cells, this phosphorylation level was enhanced only
by a factor 4, hence showing 51% decrease of the phosphorylation
level of ERK1/2 when compared to si-CTL treated cells (Fig. 5B).
Moreover, the~40% decrease of the c-myc promoter activity observed
in the presence of the si-Orai3 was almost fully restored by applica-
tion of EGF (100 nM, Supplementary Fig. 4). These results provide
supportive evidence that Orai3 speciﬁcally affects the c-myc pathway,
most likely via the MAP Kinase pathway.4. Discussion
The present study was prompted by the recent demonstration
that, in MCF-7 cancer cells, SOCE was mediated by Orai3 [8]. We
now provide compelling evidence that the early-response gene
c-myc, which is known for its implication in cell cycle progression,
proliferation and survival [12,13], is involved in the cell cycle arrest
and apoptosis seen in MCF-7 cancer cells following down-regulation
of Orai3. We also demonstrate that Orai3 and c-myc are both
up-regulated in BC tissues.
We have previously shown that Orai3 was over-expressed in 77% of
the studied cases [9].We now show that c-myc is also over-expressed in
9 out of these 13 cases, being in good agreement with previously
reported studies (see [21] for review). Importantly, using TMA on 30
BC tissues, we found that for each cancer tissue showing c-myc
over-expression, there is a concomitant up-regulation of Orai3. This
up-regulation is also found in the cancer cell line MCF-7 when com-
pared to the normal cell line MCF-10A.
We also established that Orai3 down-regulation speciﬁcally re-
duces c-myc expression and activity, Orai1 down-regulation having
opposite effects. These opposite effects could be due either to differ-
ent subcellular localization of the channels, or interaction with differ-
ent protein complexes involved in c-myc regulation. Reduction of
c-myc activity by Orai3 silencing can be due either to the obvious sub-
sequent reduction of c-myc expression levels demonstrated in the
Fig. 5. Effect of si-Orai3 and si-c-myc on Orai3 and c-myc protein expression levels. A: Representative western blot showing the effect of cell transfection with either si-CTL, si-Orai3
and/or si-c-myc on the expression of Orai3 and c-myc in MCF-7 cells. The quantiﬁcation of both proteins using densitometric analyses is shown in the lower part (n=3, pb0.01;
ns: not signiﬁcant). B: Representative western blot of pERK1/2 and ERK1/2 proteins in MCF-7 cells transfected with either si-CTL or si-Orai3. Each siRNA was tested in 0% and 5%
serum. The ratio pERK/ERK shown in the lower part corresponds to the densitometric analysis of four western blots.
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two possibilities might occur concomitantly, since it is known that
the MAP kinase pathway can control c-myc function and expres-
sion [15,33]. Orai3 down-regulation induced an approximate 51%
decrease of the phosphorylation level of ERK1/2, suggesting that
Orai3 affects the c-myc pathway most likely via the MAP Kinase path-
way. Consistent with this hypothesis, MAP kinase activation via EGF
treatment was able to suppress the inhibitory effect due to Orai3
downregulation on c-myc promoter activity. MAPKs can, for instance,
modulate the activity of c-Jun and c-Fos proteins, known to dimerize
in order to form AP-1 complexes, which are able to bind the promoter
region of c-myc. Newly synthesized c-myc can, in turn, be phosphor-
ylated by ERK on Ser 62 to induce the stabilization of c-myc (and
hence c-myc accumulation), resulting in increased expression levels
and enhanced transcriptional activity (see [34] for review). However,
the ERK pathway might not be the only one involved in c-myc activa-
tion. Indeed, other calcium-regulated transcription factors have been
shown to enhance c-myc transcription, NFAT for instance [17].
We found that si-RNAs against Orai3 and c-myc induce similar re-
ductions in BC cell viability and similar increases in BC cell mortality.
Interestingly, the effects of both si-RNAs are non-additive, suggesting
that Orai3 and c-myc might be acting in series along the same signal-
ing pathways. Furthermore, Orai3 failed to arrest normal MCF-10A
cell proliferation, most probably because of the normal c-myc expres-
sion and activity in these cells. This further conﬁrms the participation
of c-myc in the Orai3-dependent cell proliferation and survival of BC
cells.Several studies have reported that c-myc expression is Ca2+-
dependent [35,36], and is rapidly induced upon serum stimulation
[37]. On the other hand, Orai3 constitutes the main SOCE player in
MCF-7 BC cells but not in the normal MCF-10A cells [8], and hence con-
trolsMCF-7 cell proliferation and survival in a Ca2+-dependentmanner,
but fails to affect MCF-10A cell proliferation and survival [9]. Therefore,
it would appear that Orai3 controls c-myc expression and activity via a
Ca2+-dependent pathway inMCF-7 BC cells (Supplementary Fig. 5) but
not in normal MCF-10A cells.
How real activation of Orai3 occurs in MCF-7 breast cancer cells
remains to be determined. It can be hypothesized that growth factors
(e.g. EGF) and/or hormones play a role in Orai3 activation in cancer
cells. Estrogens for instance are known cancer-causing agents,
which are able to induce calcium release from the endoplasmic retic-
ulum [38,39]. This calcium release would be able in turn to activate
Orai3 channels [8,9]. Furthermore, it was recently, reported that the
activation of estrogen receptor alpha increased Orai3 expression
and SOCE in MCF-7 cells [40].
The connection between a calcium entry player and the
proto-oncogene c-myc through the calcium-dependent MAP kinase
pathway provides new clues to the downstream mechanism linking
Orai3 channels to MCF-7 BC cell proliferation, cell cycle progression
and survival. Although some questions remain, we provide a link
between Orai3 channels and a transcription factor in electrically
non-excitable cancer cells. For this reason, Orai3 could represent a
valid therapeutic target, owing to the fact that its down-regulation
affects proliferation, cell cycle progression and survival only in the
760 M. Faouzi et al. / Biochimica et Biophysica Acta 1833 (2013) 752–760MCF-7 BC cells. Although it is generally accepted that ion channels
represent attractive targets for human cancer therapy, either for
therapeutic or diagnostic purposes, efﬁcient molecules have yet to
be designed to target ion channels in breast cancer [41]. Since Ca2+
channels are easily and directly accessible via the bloodstream,
Orai3 could have potential for antibody-targeted therapeutic strate-
gies, as recently proposed for TRP ion channels [42] or voltage-gated
potassium channels [43].
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.12.009.Acknowledgments
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